Prevalence of hepatitis C in an ethnically diverse HIV-1-infected cohort in south London

HIV Medicine

Volumn 6, Issue 3, 2005, Pages 206-215

  Mohsen, A H ^a   Murad, S ^a   Easterbrook, Philippa J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Co infection; Hepatitis C; HIV 1 infection; Seroprevalence

Indexed keywords

HEPATITIS C ANTIBODY;

ADULT; ARTICLE; AWARENESS; BLOOD TRANSFUSION; CAUCASIAN; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNIC DIFFERENCE; FEMALE; HEALTH CARE FACILITY; HEPATITIS C; HEPATITIS C VIRUS; HETEROSEXUALITY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOBLOTTING; INTRAVENOUS DRUG ABUSE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NEGRO; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SCREENING TEST; SEX DIFFERENCE; UNITED KINGDOM; VIRUS TRANSMISSION;

ADULT; AFRICA SOUTH OF THE SAHARA; AWARENESS; CARIBBEAN REGION; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; EUROPE; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; LOGISTIC MODELS; LONDON; MALE; PREVALENCE; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 19644378662     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2005.00291.x     Document Type: Article

References (47)

1. Mohsen A, Easterbrook P, Taylor C, Norris S. Hepatitis C and HIV-1 infection. Gut 2002; 4: 601-608.
2. Nunez M, Raquel L, Luis MJ et al. Risk factors for severe hepatic injury after introduction of HAART. J Acquir Immune Defic Syndr 2001; 27: 426-431.
3. John M, Flexman J, French MAH. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease. AIDS 1998; 12: 2289-2293.
4. Lincoln D, Petoumenos K, Dore GJ. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med 2003; 4: 241-249.
5. Soriano V, Sulkowski M, Bergin C et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002; 16: 813-828.
6. Manns M, McHutchinson J, Gordon S et al. Peginterferon alfa-2b in combination with ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronichepatitis C: results of a randomised trial. Lancet 2001; 358: 958-965.
7. Fried M, Shiffman M, Reddy RK et al. Pegylated (40 kDa) interferon alfa-2a (Pegasys®) in combination with ribavirin: efficacy and safety results from a phase III, randomized, actively-controlled, multicenter trial. Gastroenterology 2001; 120 (Suppl. A55): Abstract 289.
8. Kaplan JE, Masur H, Holmes KK. Guidelines for preventing opportunistic among HIV-infected persons. Morb Mortal Wkly Rep 2002; 51: 1-46.
9. British HIV Association. British HIV Association (BHIVA) guidelines for treatment and management of HIV and Hepatitis C coinfection. October 2003. London, UK, British HIV Association, 2003.
10. Cacoub P, Geoffrey L, Rosenthal E et al. Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Disease, in 1995 and 1997. Clin Infect Dis 2001; 32: 1207-1214.
11. Mendel I, Clotteau L, Lambert S et al. Hepatitis C infection in an HIV-positive population in Normandy: antibodies, HCV RNA and genotype prevalence. J Med Virol 1995; 47: 213-216.
12. Greub G, Ledergerber B, Battegay M et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356: 1800-1805.
13. Ranger S, Aussel L, Weinbreck P et al. Seroprevalence of hepatitis C in human immunodeficiency virus infected patients. Pathol Biol (Paris) 1991; 39: 126-130.
14. Ockenga J, Tillmann HL, Trautwein C et al. Hepatitis B and C in HIV infected patients. J Hepatol 1997; 27: 18-24.
15. Buffet-Janvresse C, Peigue-Lafeuille H, Benichou J et al. HIV and HCV co-infection: situation at six French University hospitals in the year 2000. J Med Virol 2003; 69: 1-17.
16. Wright TL, Hollander H, Pu X et al. Hepatitis C in HIV-infected patients with and without AIDS: prevelance and relationship to patients' survival. Hepatology 1994; 20: 1152-1155.
17. Merrick ST, Sepkowitz KA, Boyle BA et al. Seroprevalence of hepatitis C antibody and hepatitis B surface antigenemia in a large urban HIV clinic. 12th World AIDS Conference. Geneva, Switzerland, June 1998 [Abstract 22263].
18. Vogt RL, Richmond-Crum S, Diwan A. Hepatitis C infection in human immune deficiency virus-positive cohort in Hawaii. J Infect Dis 1997; 176: 542-543.
19. Staples CT Jr, Rimland D, Dudas D. Hepatitis C in the HIV Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis 1999; 29: 150-154.
20. Tedaldi EM, Hullsiek KH, Malvestutto CD et al. Prevalence and characteristics of hepatitis C virus coinfection in human immunodeficiency virus clinical trials group: The Terry Beirn Community Programs for Clinical Research on AIDS. Infect Dis 2003; 36: 1213-1217.
21. Fultz SL, Justice AC, Butt AA et al. Testing, referral, and treatment patterns for hepatitis C virus coinfection in a cohort of veterans with human immunodeficiency virus infection. Clin Infect Dis 2003; 36: 1039-1046.
22. Fleming CA, Craven DE, Thornton D et al. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility of interferon treatment. Clin Infect Dis 2001; 32: 97-100.
23. Sulkowski MS, Moore RD, Mehta SH et al. Hepatitis C and progression of HIV disease. J Am Med Assoc 2002; 288: 199-206.
24. Soto T, Sadowski LS. Prevalence of hepatitis C among HIV patients with psychiatric and substance abuse diagnosis. 14th International AIDS Conference. Barcelona, Spain, July 2002 [Abstract ThpeC7516].
25. Bolao F, Sanvisens A, Egea JM et al. HIV-1 and hepatitis C virus infections among recent injecting drug users. 15th International AIDS Conference. Barcelona, Spain, June 2002 [Abstract MoPeC3380].
26. Braga PE, Etzel A, Cardoso MRA et al. Hepatitis C virus co-infection in PLWHA from Santos, Brazil: prevalence and associated risk factors. 15th International AIDS Conference. Barcelona, Spain, July 2002 [Abstract ThpeC7505].
27. Mendes-Correa MC, Barone AA, Guastini C. Hepatitis C virus seroprevalence and risk factors among patients with HIV infection. Revista Inst Med Trop Sao Paulo 2001; 43: 15-19.
28. Quan CM, Krajden M, Grigoriew GA et al. Hepatitis C virus infection in patients infected with human immune deficiency virus. Clin Infect Dis 1993; 17: 117-119.
29. Martial J, Morice Y, Abel S et al. Hepatitis C virus genotypes in HIV/HCV-coinfected patients: recent introduction of HCV type 4 strains in the Caribbean island of Martinique. 15th International AIDS Conference. Barcelona, Spain, July 2002 [Abstract ThPeC7506].
30. Risbud AR, Pareira M, Mehendale SM et al. Hepatitis C virus among patients attending sexually transmitted disease clinics with and without HIV-1 infection in Pune, India. 15th International AIDS Conference. Barcelona, Spain, July 2002 [Abstract WePeB6026].
31. Mehta NM, Purohit A, Haag A et al. Coinfection rate of HIV and hepatitis C virus among blood donors in Rajasthan, India. 15th International AIDS Conference. Barcelona, Spain, July 2002 [Abstract TuPeA4401].
32. Kim O, Kim S, Park M et al. Seroprevalence of sexually transmitted viruses in Korean populations including HIV-seropositive individuals. Int J STD AIDS 2003; 14: 46-49.
33. Zhang C, Rongge Y, Xueshan X et al. High prevalence of HIV-1 and hepatitis C virus coinfection among injection drug users in the southeastern region of Yunnan, China. J Acquir Immune Defic Syndr 2002; 29: 191-196.
34. Bootha JCL, O'Grady J, Neuberger J. Clinical guidelines on the management of hepatitis C, on behalf of the Royal College of Physicians of London and the British Society of Gastroenterology. Gut 2001; 49 (Suppl. I): I1-I21.
35. Department of Health. Hepatitis C. Strategy for England Department of Health, 2002. http//www.doh.gov.uk/cmo/hcvstrategy/
36. HPA Communicable Disease Surveillance Centre. AIDS/HIV Quarterly Surveillance Tables, July 2003, No. 59:03/2. London, SCIEH, 2003.
37. HPA Communicable Disease Surveillance Centre, ICH (London), SCIEH. HIV and AIDS in the United Kingdome 2001. London, 2002.
38. Bonacini M, Lin HJ, Hollinger FB. Prevalence of HCV RNA in HIV-infected patients. J Hepatol 1999; 30 (Suppl. 1): 135.
39. Bonacini M, Lin HJ, Hollinger FB. Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus. J Acquir Immune Defic Syndr 2001; 26: 340-344.
40. Chamot E, Hirchel B, Wintsch J et al. Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users. AIDS 1990; 4: 1275-1277.
41. Binfield T, Cent C. Hepatitis C in the EuroSIDA cohort of European HIV-infected patients: prevalence and prognostic value. 12th World AIDS Conference. Geneva, Switzerland, June 1998 [Abstract 22261].
42. Unlimited Anonymous Surveys Steering Group. Prevalence of HIV and Hepatitis Infection in the United Kingdom. Report from the Unlimited Anonymous Surveys Steering Group. London, UK, Department of Health, 2001.
43. Department of Health. Getting Ahead of the Curve. London, UK, Department of Health, 2002.
44. Barry R. Hepatitis C Disease Progression Model. Bristol UK, Bristol Directorate of Medicine, United Bristol Healthcare NHS Trust, 2001.
45. Soriano V, Garcia-Samaniego J. Liver biopsy in HIV-infected patients with chronic hepatitis C: pros and cons. HIV Clin Trials 2002; 3: 351-353.
46. Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV infected patients. New Engl J Med 2004; 351: 438-450.
47. Chung RT, Andersen J, Volberding P et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a for chronic hepatitis C in HIV-coinfected patients. New Engl J Med 2004; 351: 451-459.